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ABSTRACT 
 
Recent evidence indicates novel role for matrix 
metalloproteinases (MMPs), in particular gelatinase A (MMP-2), 
in the regulation of vascular biology that are unrelated to their 
well-known proteolytic breakdown of matrix proteins. We have 
previously reported that MMP-2 can modulate vascular reactivity 
by cleavage of the Gly32-Leu33 bound in big endothelin-1 (ET-
1) yielding a novel vasoactive peptide ET-1[1-32]. These studies 
were conducted to investigate whether gelatinolytic MMPs could 
affect neutrophil-endothelial cell attachment. ET-1[1-32] 
produced by MMP-2 up-regulated CD11b/CD18 expression on 
human neutrophils, thereby promoted their adhesion to cultured 
endothelial cells. ET-1[1-32] evoked release of gelatinase B 
(MMP-9), which in turn cleaved big ET-1 to yield ET-1[1-32],  
thus revealing a self-amplifying loop for ET-1[1-32] generation. 
ET-1[1-32] was rather resistant to cleavage by neutrophil 
proteases and further metabolism of ET-1[1-32] was not a 
prerequisite for its biological actions on neutrophils. The 
neutrophil responses to ET-1[1-32] were mediated via activation 
of ETA receptors through activation of the Ras/Raf-1/MEK/ERK 
signaling pathway. These results suggest a novel role for 
gelatinase A and B in the regulation of neutrophil functions and 
their interactions with endothelial cells. Here we describe the 
methods in detail as they relate to our previously published work. 
INTRODUCTION 
 
Matrix metalloproteinases (MMPs) are a class of secreted 
enzymes with major functions in the degradation and 
remodeling of all components of the extracellular matrix (1). 
Gelatinase A (MMP-2) and gelatinase B (MMP-9) cleave 
denaturated collagens and type IV collagen, which is present in 
the basement membranes. This latter action is important for the 
mobilization of stem cells (2) and migration of lymphocytes 
and tumor cells (3). An increasing body of evidence indicates 
novel roles for gelatinases in the innate and adaptive immunity 
that are unrelated to matrix remodeling. For instance, 
gelatinase B was found to process cytokines and chemokines, 
resulting in skewed immune functions (3,4); while gelatinase A 
was reported to mediate platelet aggregation (5). Gelatinase A 
can also modulate vascular reactivity by reducing the 
vasodilatory potency of calcitonin gene-related peptide through 
cleavage of the Gly14-Leu15 bound (6) and by cleavage of the 
Gly32-Leu33 bound in big endothelin-1 (ET-1) to yield a novel 
vasoconstrictor peptide ET-1[1-32] (7). On a molar basis, ET-
1[1-32] appears to be a more active peptide than the 21-amino 
acid ET-1 (7). Of particular interest, increased levels of 
gelatinase activity can often be detected with simultaneous 
increases in big ET-1 at sites of inflammation associated with 
myocardial ischemia (8,9), neointima formation (10) and 
atherosclerosis (11,12). Since these pathological conditions are Fernandez-Patron et al.    
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also characterized by increased adhesiveness of leukocytes to 
the vascular endothelium (13) and ET-1 may function as an 
autocrine/paracrine modulator of leukocyte functions (14-17), 
we investigated whether ET-1[1-32] formed by gelatinase A 
and gelatinase B could affect neutrophil adhesion to endothelial 
cells and studied the underlying molecular mechanisms. 
 
MATERIALS AND METHODS 
 
Activation of MMPs 
 
Highly purified human gelatinases A or B are commercially 
available as pro-enzymes as well as active enzymes (Chemicon 
International, Mississauga, ON, Canada). Preparations of pro-
MMP are often contaminated with small quantities of the 
corresponding active MMP. Larger quantities of active MMP 
can be obtained in the laboratory by incubating the pro-MMP 
(140 nM) with 4-aminophenylmercuric acetate (APMA, Sigma, 
1 mM). APMA was prepared freshly by dilution from a 10 mM 
stock in NaOH with 1M Tris-HCl, pH 7.5. APMA activates 
pro-MMPs by disrupting a cystein switch. The activation 
reaction was allowed to proceed for 2 hrs at room temperature. 
If needed, unreacted APMA was scavenged by addition of 
BSA to a final concentration of 50 µM. Activity of MMP-2 and 
MMP-9 was tested against an extracellular matrix protein (e.g., 
Collagen type IV, Calbiochem) and by zymography (see 
below). Activated MMPs were also able to cleave some small 
vasoactive hormone peptides. We have shown that both MMP-
2 and MMP-9 can cleave big endothelin-1[1-38] to yield two 
peptides, ET-1[1-32] and ET-1[33-38] (7,18). Only ET-1[1-32] 
has known biological activities, which were first discovered 
using an in vitro arterial system upon the preparation of the 
peptide in vitro (7). 
  
In vitro preparation and characterization of ET-
1[1-32] 
 
ET-1[1-32] was prepared as described previously by cleaving 
synthetic human big ET-1 (Sigma-Aldrich, Oakville, ON, 
Canada) with activated MMPs. The cleavage reaction was 
conducted for 16 h at 37°C in HEPES-phosphate saline solution 
(in mM: NaCl 142, KCl 4.7, MgSO4 1.17, CaCl2 1.56, HEPES 
10, KH2PO4 1.18; pH 7.4).  
 
HPLC analysis: The incubation mixture was separated on an 
HPLC-chromatograph (Waters) using a 12.5 cm x 4 mm C-18 
column (LiChrospher, Merck) with a (1% per minute)-gradient of 
5% CH3CN in 0.1% aqueous TFA against 0.1% TFA in 
acetonitrile at 0.5 ml/min flow rate.  
 
Mass analysis: HPLC resolved peaks were collected and the mass 
of peptides was determined with a Voyager Elite matrix assisted 
laser desorption ionization (MALDI) mass spectrometer (Applied 
Biosystems, Framingham, MA) equipped with delayed extraction 
and a reflectron. The instrument was run in the reflectron mode 
using 20 kV acceleration. External calibrations were completed 
using a mixture of known peptides. Samples were analysed 
using a two-layer preparation method (19).  The first layer was 
0.7 µL of 5 mg/ml sinapinic acid (Aldrich) in 3:2 acetone: 
methanol.  The second layer was 0.4 µl of a 1:1 mixture of the 
sample solution and sinapinic acid solution.  The second layer 
sinapinic acid solution was prepared at a concentration of 10 
mg/ml in 1:1 acetonitrile: 0.1% trifluoroacetic acid (aq.) 
(Supelco).  After the second layer dried, the sample spot was 
rinsed to remove excess salts by placing a 5 µl drop of 0.1% 
TFA on top of the sample spot and then removing the drop 
using a Kimwipe. 
For the studies, ET-1[1-32] stock solution (10
-4 M) was diluted in 
phosphate buffered saline, containing 0.1% bovine serum 
albumin, pH 7.4 immediately before use. Endotoxin 
concentration of ET-1[1-32] preparations was below the detection 
limit (0.125 EU/ml) of the Limulus amebocyte lysate assay (E-
Toxate, Sigma). 
 
Isolation and treatment of neutrophil granulocytes 
 
Neutrophil granulocytes were isolated from the peripheral 
venous blood obtained from non-smoking healthy volunteers 
by dextran sedimentation, centrifugation through Ficoll-
Hypaque gradients (Pharmacia Diagnostics AB) and hypotonic 
lysis of red blood cells (17). Neutrophils (10
7cells/ml, purity 
>97%) were re-suspended in a modified Hanks’ balanced salt 
solution (in mM: NaCl 140, KCl 5, K2PO4 10, CaCl2 1.4, 
MgCl2 1.2, glucose 5, and 0.1% bovine serum albumin, pH 
7.4), pre-incubated with enzyme inhibitors, as indicated, then 
challenged with ET-1[1-32] for the indicated times at 37ºC. The 
cells were then pelleted, and pellets and supernatants were 
collected for further analysis. 
 
Flow cytometry analysis of adhesion molecule 
expression 
 
Direct immunofluorescence labeling of control or treated 
neutrophils was performed as described previously (20). In 
brief, leukocytes were stained with a saturating concentration 
of FITC-labeled anti-human L-selectin monoclonal antibody 
(mAb) DREG-56 (IgG1, PharMingen) or R-phycoerythrin-
labeled anti-human CD11b mAb Leu-185 (IgG1, BD 
Biosciences). Appropriately labeled, class-matched irrelevant 
mouse IgG1 was used as a negative control for each staining. 
Single or double-color immunofluorescence was analyzed by a 
FACScan flow cytometer (Becton Dickinson 
Immunocytometry Systems) with Lysis II software. 
 
Activation of the Ras/Raf-1/MEK/ERK signaling 
pathway 
 
Neutrophils were lysed in ice-cold lysis buffer (in mM: Tris 20, 
EGTA 1, Na3VO4 2, NF 25, 0.5% Triton X-100, PMSF 2, 
aprotinin 40 µg/ml and 10 µg/ml each of pepstatin A, 
chymostatin and leupeptin, pH 7.4) for 15 min on ice, and Fernandez-Patron et al.    
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centrifuged at 4ºC for 10 min at 14,000 g. Western blot 
analysis of phosphorylated MEK and ERK 1/2 was performed 
using the Phospho Plus MEK 1/2 and ERK 1/2 MAP kinase 
antibody kits (New England Biolabs, Beverly, MA) as 
described (21). ERK 1/2 activity was assayed following 
immunoprecipitation of ERK 1/2 from the cell lysates with an 
immobilized anti-phospho-p44/p42 MAP kinase antibody 
(New England Biolabs) using Elk-1 fusion protein, as a 
specific target for ERK 1/2  (22). Phosphorylation of ERK 1/2 
at Ser383 was quantified by densitometry following 
immunoblotting by using an affinity purified anti-phospho-Elk-
1 polyclonal antibody (New England Biolabs) and 
chemiluminescence detection (Lumi-Light Western Detection 
Substrate, Roche Diagnostics). 
Raf-1 kinase assay: Raf-1 activity was determined by using the 
method of Garner et al. (23) with modifications. In brief,  Raf-1 
was immunoprecipitated from the neutrophil lysates with an 
anti-Raf-1 antibody (C-12, Santa Cruz Biotechnology, Santa 
Cruz, CA), antigen-antibody complexes were then isolated by 
protein A-Sepharose CL-4B (Sigma), and Raf-1 activity was 
measured using the Raf-1 Kinase Cascade Assay kit (Upstate 
Biotechnology, Lake Placid, NY) in accordance with the 
manufacturer’s protocol. 
 
Ras activation assay: Activated p21
Ras (Ras-GTP) from 
neutrophil lysates was affinity purified by using GST-Ras 
binding domain of Raf-1 (residues 1-149) fusion protein 
conjugated to agarose beads (Upstate Biotechnology) (24). The 
beads were washed extensively and boiled in reducing sample 
buffer. The eluted proteins were resolved on a 10% SDS-
polyacrylamide gel, transferred to a PVDF membrane, probed 
with a mouse anti-Ras mAb (clone RAS10, Upstate 
Biotechnology), and visualized using a goat anti-mouse 
secondary antibody conjugated to horseradish peroxidase 
(BioRad) and a chemiluminescence detection system (Lumi-
Light Western Detection Substrate, Roche Diagnostics). 
 
Metabolism of ET-1[1-32] 
 
Measurements were performed as previously described for ET-
1[1-38] and ET-1[1-21] (25). Briefly, ET-1[1-32] (100 pmol) 
was incubated with preparations of neutrophil cytosol (0.5 - 5 
µg protein) or membrane (0.2 - 2 µg protein) at 37°C for 2 hrs. 
The incubation mixture was separated on HPLC and the 
resolved peaks were collected and further characterized on a 
MALDI mass spectrometer, as described above.  
 
Measurement of gelatinase release 
 
Gelatinolytic activity released from unchallenged and 
challenged neutrophils was determined using [
3H]-acetylated 
gelatin as a substrate following activation of the latent 
gelatinase by 1.7 mM phenylmercuric acetate (26). Gelatinase 
released was expressed as the percentage of total enzyme units 
released from neutrophils treated with 0.1 % Triton X-100.  
 
Zymographic analysis of MMPs 
 
The gelatinolytic activity of neutrophil MMPs was measured 
essentially as described before (7). The samples of conditioned 
supernatants and neutrophil homogenate were mixed with 
electrophoresis loading buffer (10:1, vol:vol, 20 µl per well) 
and subjected to electrophoresis, which was carried out on a 
7.5% SDS-PAGE co-polymerized with gelatin (2 mg/ml). 
Gelatin was added from a 10 fold concentrated stock 
containing pre-boiled gelatin type A (20 mg/ml, Sigma, Cat. # 
G 8150) and 1% SDS. Following electrophoresis, gels were 
washed with 2.5% Triton X-100 for 1 hr (3 times, 20 min each) 
and incubated for 48 hrs in enzyme assay buffer (25 mM Tris, 
pH 7.5, 5 mM CaCl2, 0.9% NaCl, 0.05% Na3N) for the 
development of enzyme activity bands. After incubation, the 
gels were stained with 0.05% Coomassie brilliant blue G-250 
in a mixture of methanol: acetic acid: water (2.5: 1: 6.5) and 
de-stained in 4% methanol with 8% acetic acid. The 
gelatinolytic activities were detected as transparent bands 
against the background of Coomassie brilliant blue-stained 
gelatin. If more sensitivity was necessary, the gels were further 
destained in a solution of 1% Triton x-100 (1–2 hrs). This 
procedure increased the signal-to-noise ratio, allowing the 
visualization of faint gelatinase bands at 92, 125 and > 200 
kDa. To measure the activities of the detected enzymes, 
zymograms were read using a ScanJet 3c scanner (Hewlett 
Packard, Boise, ID). The intensity of the bands was expressed 
as arbitrary units and analyzed using SigmaGel measurement 
software (Jandel Corporation, San Rafael, CA). 
 
Neutrophil-endothelial cell adhesion assay 
 
Culture of endothelial cells: Human coronary artery endothelial 
cells (HCAEC, cryopreserved in passage 3) obtained from 
Clonetics/BioWhittaker were cultured in T25 flasks (26). 
HCAEC (passages 4 to 6) seeded into 96-well microplates 
(Sarstedt) and grown to confluence were used in the adhesion 
assays. 
 
Adhesion assay: Monolayers of HCAEC in 96-well 
microplates were stimulated with bacterial lipopolysaccharide 
(1 µg/ml, E. coli O155:B4, Sigma) for 4 h at 37ºC in a 5% CO2 
atmosphere. The cells were then washed three times with PBS, 
and 2x10
5 
51Cr-labeled neutrophils in 100 µl were added. In 
some experiments, ET-1[1-32] was added with neutrophils to 
activated HCAEC. After incubation for 30 min at 37ºC on an 
orbital shaker at 90 rpm, loosely adherent or unattached 
neutrophils were washed three times, and the endothelial 
monolayer plus the adherent neutrophils were lysed in 150 µl 
of 0.1% Triton X-100 in water. The number of adherent Fernandez-Patron et al.    
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neutrophils in each experiment was estimated from the 
radioactivity of a control sample. 
 
Statistical analysis 
 
Results are reported as means ± SEM. Statistical comparisons 
were made by ANOVA using ranks (Kruskal-Wallis test), 
followed by Dunn’s multiple contrast hypothesis test to 
identify differences when various treatments were compared to 
the same control or by the Mann-Whitney test for unpaired 
observations. P values < 0.05 were considered significant for 
all tests.  
RESULTS AND DISCUSSION 
 
Neutrophil gelatinase cleaves big ET-1 to yield 
ET-1[1-32] 
 
Neutrophils can metabolize big ET-1 into smaller peptides 
(25). When big ET-1 was incubated with neutrophil cytosol 
and membrane fractions and the resultant incubates were 
analyzed using mass spectrometry or HPLC/mass 
spectrometry, fragments of ET-1[1-38] including ET-1[23-38], 
ET-1[1-22], ET-1[1-20], ET-1[1-19] and ET-1[1-18] were 
detected (Fig. 1A). Gelatin-zymography revealed the presence of 
gelatinase B, but not gelatinase A, in both cytosol and membrane 
preparations of human neutrophils (18). Since gelatinase A can 
cleave big ET-1 to ET-1[1-32] (7); we tested whether gelatinase 
B also possess a similar activity. Indeed, APMA-activated 
gelatinase B cleaved big ET-1 to yield ET-1[1-32], as 
demonstrated using HPLC and MALDI-TOF mass spectroscopy 
(Fig. 1B). 
 
 
Fig. 1: HPLC/MALDI-TOF analysis shows that big ET-1 (ET-
1[1-38]) is cleaved to yield  many smaller peptides by 
proteases in the cytosol and cell membrane of neutrophils. 
Based on their masses, these peptides were assigned the ET-
sequences indicated in brackets. (A). Bar: peaks in the region 
of the HPLC chromatogram corresponding to neutrophil 
proteins, not ET peptides. Mass analysis on a MALDI TOF 
instrument reveals that MMP-9 (gelatinase B), cleaves big ET-
1 to yield ET-1[1-32] (B). 
 
It is not clear whether neutrophils are a major source of 
bioactive ET peptides, such as ET-1[1-21] and ET-1[1-32]. 
Neutrophils contain predominantly pro-MMP-9, not active 
MMP-9 (18). Therefore, the conversion of big ET-1 into ET-
1[1-32] is likely regulated by a specific MMP-9 activation 
event (that occurs during or following release of granule 
contents) as well as by rapid peptide degradation. In line with 
this, only small quantities of ET-1 peptides were detected with 
our HPLC/mass spectrometry assays (Fig. 1A). 
 
Metabolism of ET-1[1-32] by neutrophils 
 
We next investigated whether further cleavage of ET-1[1-32] was 
a requirement for its bioactivity. ET-1[1-32] (100 pmol) was 
incubated with preparations of neutrophil cytosol (0.5-5 µg 
protein) or membrane (0.2-2 µg protein) and assessed for 
conversion into smaller peptides. There was little conversion of 
ET-1[1-32] into other smaller peptides such as ET-1[1-22], ET-
1[1-21], ET-1[1-20] and ET-1[1-19] using a combination of 
HPLC with mass spectroscopy (18). Consistent with these 
observations, the effects of ET-1[1-32] on adhesion molecule 
expression were insensitive to phosphoramidon, an inhibitor of 
the metal-dependent endothelin converting enzymes (L-selectin 
expression was 35±6% and 31±7% of control, CD11b expression 
178±17% and 184±16% of control in response to 100 nM ET-
1[1-32] in the absence or presence of phosphoramidon, 
respectively, n=5, P>0.1) (18).  
 
To further confirm that the biological effects of ET-1[1-32] 
were due to the inherent bioactivity of this peptide, neutrophils 
were challenged with big ET-1 (100 nM), the inactive precursor 
of ET-1 peptides, in the presence of phosphoramidon (an 
endothelin converting enzyme inhibitor) and o-phenanthroline 
(an MMP inhibitor). There were no detectable changes in 
adhesion molecule expression on neutrophils under these 
conditions (L-selectin and CD11b/CD18 expression were 
110±6% and 102±3% of control, respectively, n=4, P>0.1) 
(18). 
 
ET-1[1-32] induces gelatinase release from 
neutrophils 
 
Next, we investigated whether ET-1[1-32] is capable of 
inducing gelatinase release from human neutrophils. Indeed, 
ET-1[1-32] evoked a concentration-dependent release of 
gelatinase (Fig. 2) without affecting cell viability (data not Fernandez-Patron et al.    
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shown). Since neutrophils contain only gelatinase B, but not 
gelatinase A, and both gelatinase A and B are capable of 
cleaving big ET-1 to yield ET-1[1-32], a self-amplifying loop 
may exist for stimulation of ET-1[1-32] formation and 
gelatinase B release and consequently for neutrophil activation. 
Intriguingly, ET-1[1-32] appears to function as a partial 
neutrophil agonist, for it did not induce superoxide formation 
(18). 
 
ET-1[1-32] induces L-selectin shedding and up-
regulates CD11b/CD8 expression on neutrophils 
 
ET-1[1-32] induced a rapid down-regulation of L-selectin and 
up-regulation of CD11b/CD18 on the surface of neutrophils 
(Fig. 3). These actions of ET-1[1-32] were concentration-
dependent with EC50 values of 1 to 3 nM (18). Consistent with 
previous observations (7), on a molar basis ET-1[1-32] 
appeared to be a more potent neutrophil agonist than ET-1 
(17,18). Our previous pharmacological and receptor binding 
studies showed that human neutrophils predominantly express 
ETA receptors (17). Consistently, the actions of ET-1[1-32] on 
neutrophil expression of L-selectin and CD11b/CD18 as well 
as gelatinase release were almost completely inhibited by the 
selective ETA receptor antagonist FR139317, but not by the 
ETB receptor-selective antagonist BQ788 (18). 
 
 
Fig. 2: ET-1[1-32] induces gelatinase release from human 
neutrophils. Isolated neutrophils were challenged with ET-1[1-
32] for 30 min at 37°C. Gelatinase released into the culture 
medium was measured as described in Methods and is 
expressed as percentage of total cellular enzyme activity. N=4, 
P<0.05 vs unstimulated. 
 
 
Fig. 3: Effects of ET-1[1-32] on surface expression of adhesion 
molecules on human   neutrophils. Neutrophils were 
challenged with 100 nM ET-1[1-32] for 30 min at 37°C, then 
stained with fluorescein-labeled anti-L-selectin and anti-
CD11b monoclonal antibodies. C, negative control of 
immunostaining with irrelevant antibodies. Results are 
representative of  6 experiments. 
 
ET-1[1-32] activates ERK through the Ras/Raf-
1/MEK pathway 
 
Experiments with PD98059, which inhibit the activation of 
MEK and consequently of ERK, revealed that neutrophil 
responses to ET-1[1-32] were ERK-dependent (18). However, 
PD98059 was more effective in reversing ET-1[1-32]-induced 
up-regulation of CD11b/CD18 expression  and gelatinase 
release (72±5% and 80±5% inhibition, respectively), than 
down-regulation of L-selectin expression (59±4% inhibition) 
(18). To provide direct evidence for the involvement of the 
Ras/Raf-1/MEK/ERK signaling pathway, we studied activation 
of this cascade. ET-1[1-32] induced rapid (within 2 min) 
association of GTP-bound active Ras with the glutathione-S-
transferase-Ras binding domain of Raf-1 (Fig. 4A) and 
increased Raf-1 kinase activity (Fig. 4B). Consequently, 
enhanced phosphorylation of MEK and ERK was also detected 
within 5 min of addition of ET-1[1-32] (Fig. 4C). 
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Fig. 4: ET-1[1-32] activates the Ras/Raf-1 kinase/MEK/ERK 
1/2 signaling pathway. A, Ras was detected by immunoblotting 
following affinity precipitation of GTP-bound active Ras from 
lysates of neutrophils. B, Raf-1 kinase activity was determined 
using a MAPK cascade system following immunoprecipitation 
of Raf-1. C, MEK and ERK 1/2  phosphorylation was detected 
by immunoblotting. Neutrophils were challenged with ET-1[1-
32] for 2 min (A,B) or 5 min (C). Results are representative of 
3 independent experiments. 
 
These actions of ET-1[1-32] were concentration-dependent and 
was comparable to those evoked by 100 nM platelet-activating 
factor (18). ET-1[1-32]-induced ERK phosphorylation was 
inhibited by 75±6% with PD98059 (18). The similar degree of 
inhibition of ERK phosphorylation and CD11b/CD18 
expression and gelatinase release observed with PD98059 
indicates a tight correlation between ERK activation and 
neutrophil responses to ET-1[1-32]. It should be noted that the 
inhibition was incomplete, indicating the involvement of other 
signaling pathways.   
 
ET-1[1-32] promotes neutrophil adhesion to 
human coronary artery cells in vitro 
 
To assess the biological significance of ET-1[1-32]-induced 
changes in expression of adhesion molecules on the neutrophil 
surface, we performed a neutrophil-endothelial cell adhesion 
assay. To mimic blood flow, the assay was performed under non-
static conditions (26). While ET-1[1-32] did not stimulate 
neutrophil adhesion to monolayers of unstimulated HCAEC, 
about 1.5-fold more neutrophils adhered to LPS-stimulated 
HCAEC when neutrophils were added to HCAEC together with 
ET-1[1-32] than in the absence of ET-1[1-32] (Fig. 5). Since 
neutrophils were incubated in the adhesion assays for 30 min with 
activated HCAEC, stimulation of neutrophil adhesion by ET-1[1-
32] can be attributed primarily to the effects of this peptide on 
neutrophils. Indeed, much longer periods of culture of HCAEC 
with ET-1[1-32] were required to detect slight increases in 
expression of E-selectin and ICAM-1 on HCAEC (18). 
 
 
 
Fig. 5: ET-1[1-32] enhances adhesion of  neutrophils (PMN) to 
monolayers of human coronary artery endothelial cells 
(HCAEC). HCAEC were incubated with LPS (1 µg/ml) for 4 h, 
washed and PMN  without or together with ET-1[1-32] (30 
nM) were then added for 30 min at 37°C. Values are means ± 
SEM (n=5). 
 
 
No adhesion experiments were performed with neutrophils alone 
pre-incubated with ET-1[1-32] since this peptide may induce 
neutrophil aggregation through up-regulation of CD11b/CD18 
expression, thereby making interpretation of the results difficult. 
Our studies with function-blocking monoclonal antibodies 
revealed that ET-1[1-32]-induced neutrophil adherence to 
activated HCAEC were predominantly mediated through CD18 
integrins and their endothelial counter-ligand, ICAM-1 (18). 
 
 
CONCLUSIONS 
 
Our results showed that two MMPs, gelatinase A and B, via 
cleavage of big ET-1 could affect expression of adhesion 
molecules on human neutrophils and consequently promote 
their adhesion to endothelial cell. Such actions may have 
relevance to pathological conditions where simultaneous over-
expression of gelatinolytic MMPs and big ET-1 can be 
detected at the sites of tissue injury and inflammation. Thus, 
gelatinase A and B, often considered as pure effector 
molecules, may act as amplifiers of leukocyte recruitment, one 
of the key events of inflammation. Finally, gelatinases 
constitute a prototypic example of the regulation of innate 
immune reactions by proteolysis. 
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PROTOCOLS 
 
Protocol I: Zymography 
Gelatin-SDS-zymography technique 
 
1.  Prepare a gel following a standard SDS-PAGE protocol with the exception that gelatin is added to the gel solution. For the 
detection of MMP-2 and MMP-9 gelatinolytic activity, the recommended composition is 7.5% acrylamide. Cast SDS-
PAGE gel according to the procedure of Laemmli E.K. (Nature, 227, 1970, 680-685). An updated procedure is described 
in Current Protocols in Molecular Biology, Greene Publishing Associates and Wiley-Interscience, 1991, Vol. 2 pp 10.2.4-
10.2.9. However, replace water in the procedure for gelatin (Gelatin, type A, from pork skin, electrophoresis reagent, 
Sigma cat # G-8150). Final concentration of gelatin should be between 0.5 and 2.0 mg/ml (recommended is 2 mg/ml).  
2.  Run the gel at 4ºC. Before starting the electrophoresis cool down the running buffer solution.  
3.  After the electrophoresis is complete, wash the gel with an aqueous solution of Triton X-100 (2.5%) (3 times 20 min) at 
room temperature. 
4.  Replace Triton for enzyme assay buffer (Tris-HCl, pH 7.6, supplemented with 0.15 M NaCl, 5 mM CaCl2, and 0.05% 
NaN3). Incubate the gel at 37ºC for 24 hrs. Low activity bands may require longer incubation (48 hrs). 
5.  Replace enzyme assay solution for Coomassie Blue stain (0.05% Coomassie Brilliant Blue, 10 % acetic acid, 30% 
methanol). 
6.  Gelatinase bands are detected as clear bands contrasting against the blue stained gel background. Sensitivity of this 
procedure is in the 50 to 100 pg range for MMP-2. 
 
 
Protocol II: Analysis of metabolism of ET peptides by neutrophils 
Peptide metabolism reactions 
 
1.  Solutions of ET-1[1-38] and ET-1[1-32] peptides (10
-4 M) in HEPES-phosphate saline solution (in mM: NaCl 142, KCl 4.7, 
MgSO4 1.17, CaCl2 1.56, HEPES 10, KH2PO4 1.18; pH 7.4) are incubated with neutrophil cytosol or membrane fractions 
for various times (from 30 minutes to 30 hrs) at 37ºC and in two dilutions containing a total of 2 µg and 0.2 µg protein. 
Control incubations are carried out with APMA-activated MMP-2 and MMP-9 to confirm cleavage of big ET-1 to ET-
1[1-32]. 
2.  Snap freeze the peptide digest until analysis by matrix assisted laser desorption ionization (MALDI)- time of flight (TOF) 
mass spectrometry (MS). MALDI-TOF MS is chosen for being relatively tolerant to the presence of salts and detergents 
in the peptide preparation.  
Sample preparation for MALDI 
 
1.  Our Voyager Elite matrix assisted laser desorption ionization (MALDI) mass spectrometer (Applied Biosystems, 
Framingham, MA) is equipped with delayed extraction and a reflectron. The instrument is run in the reflectron mode 
using 20 kV acceleration.  
2.  Complete external calibration using a mixture of known peptides.  
3.  Analyse samples using a two-layer preparation method. The first layer is 0.7 µl of 5 mg/ml sinapinic acid (Aldrich) in 3:2 
acetone: methanol. The second layer is 0.4 µl of a 1:1 mixture of the sample solution and sinapinic acid solution.  The 
second layer sinapinic acid solution was prepared at a concentration of 10 mg/ml in 1:1 vol/vol acetonitrile: 0.1% 
trifluoroacetic acid (aq.) (Supelco). Wait until the second layer is completely dry. Rinse the sample spot to remove excess 
salts by placing a 5 µl drop of 0.1% TFA on top of the sample spot and then remove the drop using a Kimwipe.  
HPLC analysis and HPLC/MS analysis 
 
1.  Mass analysis offers quick insight into the metabolism of peptides, reflecting possible cleavage by proteases and the mass 
of the resulting fragments. To confirm the results from MALDI-MS analysis, it is useful to fractionate the ET peptides and 
subcellular fractions on an HPLC provided with a C18 column and analyze each fraction separately.  Fernandez-Patron et al.    
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2.  Separation on a C18 column is largely based on the differential hydrophobic property of peptides and proteins. It is a 
method of choice for separation and analysis of peptides and soluble proteins. Upon developing a gradient of 0.1% TFA 
against and acetonitrile, ET peptides of different lengths are resolved in time. Elution of peptides is detected using an on-
line UV absorbance detector (210 nm) as absorbance peaks. 
3.  The components that elute from the HPLC C18 column are collected in separate plastic vials and frozen for later analysis 
by MALDI-TOF MS.  
4.  MALDI analysis is used to assign a mass to every component after it has been resolved on the C18 column, thus 
facilitating component identification. Other alternative mass spectrometry methods such as liquid chromatography (LC) 
quadrupol time of flight (Q-TOF) MS might be employed for the on-line sequencing of LC peptides. The above described 
MALDI-TOF MS method is useful for most applications and alone has a high sensitivity of detection (in the low femto- to 
attomol levels). Importantly, HPLC with absorbance detection can be used for quantitative purposes. However, HPLC 
retention time does not allow identification. Protein and peptide identification is possible by coupling HPLC with 
spectrometry techniques. However, mass spectrometry does not easily allow for quantification. This is due to the fact that 
peptide ionization in the mass spectrometer is affected by the presence of other components of the sample, including other 
peptides.  Nevertheless, mass spectrometry can be very powerful in the qualitative analysis as well as in following up the 
enzymatic conversion of proteins and peptides. 
 
 
Protocol III: Quantification of gelatinase release from neutrophils 
Preparation of [
3H]-acetylated gelatin 
 
1.  Type I collagen (50 mg, Sigma) is dissolved in 25 ml 0.05% acetic acid. Gelatin is obtained from collagen by denaturation 
at 45ºC for 1 hr. 
2.  Dialyze extensively against 100 mM phosphate buffer containing 140 mM NaCl, 20 mM KCl and 50 mM sodium acetate. 
3. To  prepare  [
3H]-acetylated substrate, the dialyzed gelatin solution is mixed with 0.1 mmol [
3H]-acetic anhydride (50 
Ci/mmol, NET-018A, DuPont NEN) in 0.5 ml acetonitrile with stirring and kept at 4ºC for 60 min. Acetic anhydride is 
supplied in 5 µl benzene in a break seal glass tube. Immediately before use, the tube should be immersed in liquid 
nitrogen for 20 sec, then add 500 µl of acetonitrile to the upper compartment and break the seal. The flow of acetonitrile 
into the lower compartment is relatively slow (20-25 min).  
4.  The acetylated gelatin should be dialyzed against three changes of 50 mM Tris/HCl, pH 7.6, containing 50 mM NaCl.   
5. Determine  incorporated  radioactivity, and store the acetylated gelatin at 4ºC. 
Gelatinase assay 
 
Materials: di-isopropyl-phosphoro-fluoridate (DFP)-treated samples, [
3H]-acetylated gelatin, buffer A: 50 mM Tris/HCl, pH 7.6 
containing 50 mM NaCl, 0.064% Triton X-100, 12.8 mM CaCl2, 2.57 mM p-amino-phenylmercuric acetate and 0.13 mg/ml 
bovine serum albumin. 
 
1.  Following incubation of neutrophils with appropriate stimuli, prepare cell supernatant by centrifugation (400 g 15 min). 
For total neutrophil gelatinase content, lyse the cells with 0.1 % Triton X-100 and collect supernatant after centrifugation 
at 10,000 g for 15 min. 
2. Mix  40  µl cell supernatant with equal volume of buffer B (100 mM Tris/HCl, pH 7.6 containing 6 mM DFP, 100 mM 
NaCl and 0.1% Triton X-100) and incubate for 60 min at 37ºC. Run all conditions in duplicate. 
3.  Stop the reaction by adding 4 µl of bovine serum albumin solution (2 mg/ml). 
4. Mix  20  µl of [
3H]-acetylated gelatin solution, 30 µl of DFP-treated sample and 175 µl buffer A in an Eppendorf tube. 
5.  Incubate mixture for 60 min at 37ºC. 
6.  To stop the reaction, add 25 µl BSA solution (100 mg/ml in 50 mM Tris/HCl, pH 7.6 containing 50 mM NaCl). Vortex. 
7. Add  50  µl ice-cold TCA (90% weight/vol), vortex, and keep samples on ice for 30 min. 
8.  Centrifuge with 1250 g for 15 min at 4ºC. 
9. Transfer  100  µl supernatant into liquid scintillation vials, overlay with scintillation fluid and read in scintillation counter. 
10.  Calculate gelatinase release as the percentage of total cellular gelatinase content. 
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Protocol IV: Measurement of Ras and Raf-1 kinase activity 
 
Affinity precipitation and detection of activated Ras 
 
1.  Following challenge of neutrophils (10
7 cells/ml, 400 µl) with stimuli for 1 to 5 min, centrifuge the cells with 400 g for 5 
min at 4ºC. Discard supernatant. 
2.  Lyse the cells for 15 min on ice in 150 µl lysis buffer (25 mM HEPES, pH 7.5, 150 mM NaCl, 1% Igepal CA-630 
(Sigma), 10 mM MgCl2, 1 mM EDTA and 2% glycerol). 
3.  Centrifuge with 14,000g for 10 min at 4ºC.  
4.  Transfer supernatant into new Eppendorf tubes. Determine protein concentration and adjust protein concentration to 
1mg/ml with lysis buffer.  
5.  Add 1/10 volume of glutathione agarose, 50% slurry and incubate for 15 min at  4ºC on a rotator (Adams Nutator). 
Glutathione agarose should be prepared in advance by swelling glutathione immobilized on cross-linked 4% beaded 
agarose (Sigma, G-4510) in water at 200 ml/g for 2 hours. This suspension can be stored at 4ºC. Immediately before use, 
remove an aliquot, wash it twice with equal volume of water, then three times with equal volume of lysis buffer, and re-
suspend in 0.5 volume of lysis buffer. 
6. Add  10  µl of Raf-1 RBD agarose conjugate (Upstate Biotechnology) and incubate at 37ºC for 15 min with gentle 
agitation. 
7.  Centrifuge with 12,000 g for 5 sec. Discard supernatant. 
8.  Wash beads five times with 400 µl lysis buffer. Collect the agarose beads by 5 sec centrifugation in the microcentrifuge at 
14,000 g, and drain off the supernatant. 
9.  Resuspend the agarose beads (approx. 15 µl)  in 15 µl Laemmli loading buffer 2x and boil for 5 min.  
10.  Perform SDS-polyacrylamide gel electrophoresis on 20 µl supernatant and transfer the proteins to nitrocellulose. Perform 
western blotting using anti-Ras monoclonal antibody (clone RAS10, Upstate Biotechnology cat. No. 05-516) at 1 µg/ml 
final concentration. 
11.  Stimulation of cells will activate approximately 10-15% of the available Ras; in vitro GTP-γS protein loading will 
activate nearly 100% of the Ras that can be activated. To activate Ras with GTP-γS protein, incubate 1 ml of cell lysate 
with GTP-γS (final concentration 0.1 mM) in the presence (positive control) and absence of EDTA (10 mM) (negative 
control) at 30ºC for 15 min with agitation. Terminate the reaction by placing the tubes on ice and adding MgCl2 to a final 
concentration of 60 mM. Then proceed as described under point 4. 
 Immunoprecipitation and detection of Raf-1 
 
1.  Following incubation with appropriate stimuli, pellet neutrophils by centrifugation. Lyse cells by adding 1/10th volume of 
RIPA buffer pH 7.2 (100 mM Na2PO4, 150 mM NaCl, 2 mM EDTA, 1% sodium deoxycholate, 1% Nonidet (NP-40), 
0.1% SDS, 10 µg/ml aprotinin, 2 mM PMSF, 0.001% β-mercaptoethanol, and 0.8 mM sodium orthovanadate) for 15 min 
on ice. 
2.  Centrifuge in a microcentrifuge with 14,000 g for 15 min at 4ºC. 
3.  Transfer supernatant into new Eppendorf tubes. Add 1 µl anti-Raf antibody (C-12, Santa Cruz Biotechnology, Santa Cruz, 
CA) or monoclonal rabbit IgG (SC-133, Santa Cruz Biotechnology) per 100 µl supernatant. Incubate on a rotator for 60 
min at  4ºC. 
4. Add  4  µl  protein A-Sepharose CL4B per 100 µl supernatant, and incubate on a rotator for 60 min at  4ºC. Protein A-
Sepharose CL4B (Sigma, cat. # P-3391) should be prepared in advance. Suspend protein A-Sepharose CL4B at 50 mg/ml 
in PBS for 1 hr at 4ºC, centrifuge with 800 g for 10 min at 4ºC, wash 5 times with equal volume of RIPA buffer, and 
finally resuspend it in 0.5 volume of RIPA buffer and store at 4ºC.  
5.  Centrifuge with 800-900 g for 20 min at 4ºC. 
6.  Wash the pellets twice with 0.5 ml RIPA buffer, then twice with 0.5 ml PAN buffer (100 mM PIPES, pH 7.4, 100 mM 
NaCl) containing 30 µg/ml aprotinin, and once with 0.5 ml PAN buffer. Re-suspend pellets in 5 µl PAN buffer. 
7.  To assess Raf-1 kinase activity, we used the Raf-1 Kinase Cascade Assay kit from Upstate Biotechnology (Cat. No. 17-
172). Use 4 µl of the samples in the assay and follow the manufacturer’s protocol.  
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Protocol V: Neutrophil-endothelial cell adhesion assay 
Preparation of 
51Cr-labeled neutrophils 
1.  Isolate polymorphonuclear leukocytes from peripheral blood. 
2.  Resuspend leukocytes at 2x10
7cells/ml in Hanks’ balanced salt solution, pH 7.2, 0.1% BSA. 
3. Add  56  µCi 
51Cr (sodium chromate in saline, Cat. No. NEZ030, NEN) per ml cell suspension. 
4.  Incubate for 60 min at 37ºC. 
5.  Wash cells twice with 10 ml Hanks’ balanced salt solution without calcium and magnesium. 
6.  Resuspend neutrophils at 2.5x10
6 cells/ml in RPMI 1640 medium containing 1% BSA. Check neutrophil viability using 
Trypan blue exclusion test, and determine chromium-51 incorporation into known number of neutrophils (e.g., 500,000 
cells). 
Adhesion assay 
 
1.  Endothelial cells should be grown into confluence in 96-well microplates (Sarstedt). 
2.  Change endothelial cell culture medium at least 16 hours before the experiments for RPMI 1640 medium containing 1% 
BSA. 
3.  Culture endothelial cell for 4-6 hours with LPS (1 µg/ml), TNF-α (50 ng/ml) or IL-1β (25 ng/ml) to induce near-maximum 
expression of E-selectin and ICAM-1. 
4.  Wash wells three times with 200 µl RPMI 1640, 1% FBS. 
5. Add  100  µl radiolabeled neutrophils with or without a neutrophil agonist to endothelial cells. 
6.  Incubate for 30 min at 37ºC, 5% CO2 on a horizontal rotator at 90 rpm.  
7.  Remove medium. Wash wells three times with phosphate buffered saline, pH 7.2 to remove unattached or loosely 
attached leukocytes. 
8.  Overlay wells with 150 µl 0.1% Triton X-100 solution, and incubate until cell lysis is complete. 
9. Transfer  100  µl of cell lysate into counting vials, and determine radioactivity using a γ-counter. 
10.  The number of neutrophils adhered per well can be calculated by knowing the amount of  chromium-51 incorporated into 
neutrophils. 